Table 1.
Baseline characteristics of patients enrolled
| Total | Low SHR group (SHR < 1.191) | High SHR group (SHR ≥ 1.191) | P value | |
|---|---|---|---|---|
| Number | 127 | 63 | 64 | |
| Age | 55.94 ± 11.14 | 54.33 ± 11.74 | 57.52 ± 10.36 | 0.108 |
| Male sex (%) | 110 (86.6%) | 58 (92.1%) | 52 (81.2%) | 0.116 |
| BMI (kg/m2) | 25.12 ± 2.61 | 25.48 ± 2.40 | 24.78 ± 2.78 | 0.130 |
| Hypertension (%) | 66 (52.0%) | 32 (50.8%) | 34 (53.1%) | 0.860 |
| T2DM (%) | 51 (40.2%) | 20 (31.7%) | 31 (48.4%) | 0.071 |
| Current smoker (%) | 87 (68.5%) | 47 (74.6%) | 40 (62.5%) | 0.182 |
| Killip classification | 0.405 | |||
| Class I | 115 (90.6%) | 55 (87.3%) | 60 (93.8%) | |
| Class II | 10 (7.9%) | 7 (11.1%) | 3 (4.7%) | |
| Class III | 2 (1.6%) | 1 (1.6%) | 1 (1.6%) | |
| Class IV | 0 | – | – | |
| Baseline LVEF | 49.98 ± 8.59 | 50.84 ± 9.41 | 49.13 ± 7.67 | 0.263 |
| Laboratory examination | ||||
| White blood cells (109/L) | 10.45 ± 2.47 | 10.35 ± 2.60 | 10.56 ± 2.35 | 0.639 |
| Hemoglobin (g/L) | 153.06 ± 12.96 | 152.89 ± 13.42 | 153.22 ± 12.59 | 0.887 |
| Platelet (109/L) | 229.99 ± 63.95 | 232.79 ± 65.29 | 227.23 ± 62.99 | 0.626 |
| eGFR (mmol/L) | 99.86 ± 13.44 | 101.36 ± 14.27 | 98.38 ± 12.52 | 0.213 |
| Uric acid (mg/dl) | 357.22 ± 92.63 | 365.91 ± 106.52 | 348.66 ± 76.46 | 0.297 |
| ABG (mmol/L) | 8.38 (6.95,10.87) | 6.99 (6.23,8.48) | 10.10 (8.37,11.99) | 0.001 |
| HBA1C (%) | 6.00 (5.60,6.90) | 6.00 (5.60,6.90) | 6.00 (5.53,6.80) | 0.894 |
| SHR | 1.22 ± 0.25 | 1.05 (0.95,1.11) | 1.39 (1.28,1.50) | < 0.0001 |
| Triglycerides (mmol/L) | 1.43 (1.00,1.97) | 1.81 ± 1.13 | 1.36 (0.90,1.86) | 0.116 |
| LDL-C (mmol/L) | 3.28 ± 1.06 | 3.23 ± 1.13 | 3.33 ± 0.98 | 0.586 |
| HDL-C (mmol/L) | 1.13 ± 0.28 | 1.06 ± 0.23 | 1.19 ± 0.31 | 0.010 |
| Peak CK-MB | 122.40 (45.10,258.00) | 89.38 (26.60,202.60) | 154.60 (54.18,299.00) | 0.047 |
| Peak cTnI (ng/ml) | 30.62 (12.40,78.00) | 20.62 (8.84,40.64) | 56.07 (25.43,81.00) | < 0.001 |
| Medications (Discharge) | ||||
| Aspirin (%) | 127 (100.0%) | 63 (100.0%) | 64 (100.0%) | 1.000 |
| Clopidogrel/ticagrelor (%) | 127 (100.0%) | 63 (100.0%) | 64 (100.0%) | 1.000 |
| Statin (%) | 123 (96.9%) | 63 (100.0%) | 60 (93.8%) | 0.119 |
| Beta-blockers (%) | 109 (85.8%) | 56 (88.9%) | 53 (82.8%) | 0.446 |
| ACEI/ARB (%) | 89 (70.1%) | 43 (68.3%) | 46 (71.9%) | 0.701 |
| Insulin (%) | 7 (5.5%) | 2 (3.2%) | 5 (7.8%) | 0.440 |
| Hypoglycemic agents (%) | 30 (23.6%) | 13 (20.6%) | 17 (26.6%) | 0.532 |
BMI, body mass index; T2DM, type 2 diabetes mellitus; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; ABG, admission blood glucose; HBA1C, glycated hemoglobin; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; SHR, stress hyperglycemia ratio